$10 Billion Deal, page-69

Sell side caps thinning looking at the trades, some obvious final accumulation going on before the brakes taken off and next leg up (and maybe China announcement) next week IMHO

I remind potential investors that this is a unique product -- inducing beneficial immunological changes. It targets HIV-1 in reservoirs which otherwise still remain in patients taking current antiretroviral drugs. BIT225 attacks HIV-1 in macrophage cells that current drugs cannot access. Unless macrophage cells are cleared of HIV-1 virus, a cure is not possible.

I wait to see the depth next week - if the cap >1m sells are gone - we will have our answer